Meeting Coverage > ASCO Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer — Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib ...

CHICAGO—An investigational drug called axitinib is more effective than sorafenib in prolonging progression-free survival (PFS) in patients previously treated for metastatic renal cell carcinoma ...

Oasmia barrels toward FDA filing after ovarian cancer drug clears PhIII By Nick Paul Taylor Apr 28, 2016 4:04am ovarian cancer Oasmia Clinical Data ...

OncoGenex Pharmaceuticals, Inc. OGXI announced that apatorsen plus carboplatin and Alimta (pemetrexed) failed to show statistical significance for progression-free survival (PFS) in a phase II ...

The PFS benefit in the lung trial was driven by patients with non-squamous NSCLC, who had a median PFS of 5.6 months with Dato-DXd compared with 3.7 months with docetaxel (HR 0.63, 95% CI 0.51-0.78).

The TULIP trial assessed efficacy of SYD985 in HER2-positive locally advanced or MBC that has been treated with two or more regimens.

Phase III trial data have demonstrated that therapy using Celgene’s Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) leads to longer progression-free ...

Topline results from the company’s Veritac-2 trial (NCT05654623) showed a clinically meaningful improvement in PFS in ...

As many GEN poll voters agree as disagree that the primary endpoint for approval of cancer drugs should change to progression-free survival (PFS) from overall survival (OS), with 15.8% undecided ...

CHICAGO—An investigational drug called axitinib is more effective than sorafenib in prolonging progression-free survival (PFS) in patients previously treated for metastatic renal cell carcinoma ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...